Cantor Fitzgerald Issues Negative Outlook for EYPT Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Stock analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of EyePoint Pharmaceuticals in a research report issued to clients and investors on Thursday, May 8th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings of ($3.15) per share for the year, down from their previous forecast of ($2.96). The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). The firm had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

A number of other equities analysts also recently issued reports on EYPT. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. Finally, Chardan Capital lowered their price target on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.29.

EyePoint Pharmaceuticals Stock Down 4.8%

EYPT opened at $5.81 on Monday. The stock’s fifty day moving average is $6.02 and its two-hundred day moving average is $7.49. The company has a market capitalization of $399.79 million, a P/E ratio of -2.91 and a beta of 1.58. EyePoint Pharmaceuticals has a 52 week low of $3.91 and a 52 week high of $13.99.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in EYPT. Summit Investment Advisors Inc. lifted its position in shares of EyePoint Pharmaceuticals by 39.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after buying an additional 1,940 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of EyePoint Pharmaceuticals by 3,174.4% during the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company’s stock worth $56,000 after acquiring an additional 9,936 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in EyePoint Pharmaceuticals during the fourth quarter valued at approximately $59,000. Virtus ETF Advisers LLC purchased a new stake in EyePoint Pharmaceuticals during the fourth quarter valued at approximately $67,000. Finally, AlphaQuest LLC boosted its stake in EyePoint Pharmaceuticals by 13,246.6% in the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock valued at $73,000 after acquiring an additional 9,670 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.